

Supplementary Table 1. Characteristics of patients with pure high-grade DCIS and high-grade DCIS associated with IBC included in this study.

	Pure high-grade DCIS	DCIS component (adjacent to IBC)	IBC component (adjacent to DCIS)
	n=89	n=119	n=119
Age (mean, range)	53 yrs (35-84yrs)	51 yrs (28-84yrs)	51 yrs (28-84yrs)
≥ 50yrs	46 (52%)	54 (46%)	54 (46%)
< 50yrs	43 (48%)	65 (54%)	65 (54%)
Caucasian	62 (70%)	85 (72%)	85 (72%)
Hispanic	7 (8%)	9 (7%)	9 (7%)
African-American	7 (8%)	12 (10%)	12 (10%)
Asian	2 (2%)	6 (5%)	6 (5%)
Unknown	11 (12%)	7 (6%)	7 (6%)
Post-menopausal	47 (53%)	54 (45%)	54 (45%)
HRT use ≥ 1yr prior	12 (13%)	15 (13%)	15 (13%)
ER positivity*	46 (52%)	75 (63%)	75 (63%)
PR positivity*	41 (46%)	62 (52%)	62 (52%)
HER2 positivity*	51 (57%)	73 (61%)	73 (61%)
Nuclear grade 3	89 (100%)	119 (100%)	119 (100%)
Histological grade 2	NA	NA	5 (4%)
Histological grade 3	NA	NA	114 (96%)

*All values reported for the DCIS component. DCIS, ductal carcinoma *in situ*; ER, estrogen receptor; HRT, hormone replacement therapy; IBC, invasive breast cancer; NA, not applicable; PR, progesterone receptor; yrs, years.